Search Results

Celmatix Inc.today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.

Celmatix Inc. and Aché Laboratórios, a leading Brazilian pharmaceutical company, announced a collaboration and license option agreement to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Aché, for Women’s Health indications.

Celmatix Inc., the leading women’s health biotech focused on ovarian biology, today announced its latest drug program, which is targeting melatonin receptors outside of the central nervous system (CNS).

Celmatix Inc the leading women’s health biotech focused uniquely on ovarian biology, today announced that Dr. Susan Herbert has joined the company’s board of advisors.

Celmatix Inc., the leading women’s health biotech focused on ovarian biology, today announced findings from its long-term collaboration with researchers from the University of Oxford and 24 other institutions to decode the genetic basis of endometriosis, a condition that globally impacts 1 in 10 women*

Celmatix Inc., a biotechnology company focused on ovarian biology, announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec.

Celmatix Inc. a biotechnology company focused on ovarian biology, announced the identification of a novel AMHR2 agonist compound that has demonstrated robust biological activity in multiple therapeutically relevant preclinical assays and a pharmacokinetic profile consistent with the desired product profile for an injectable drug.

Celmatix lead AMHR2 agonist compound achieves in vivo PK/PD milestone. Dr. Fauser, one of the most cited investigators in reproductive health, brings deep expertise in ovarian stimulation and pathophysiology of ovarian function to Celmatix advisory board and trial committee.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

Celmatix’s drug program works by mimicking anti-Mullerian hormone, which acts as the molecular break that keeps women from depleting their ovarian reserves too quickly.